What's on this Page
What proportion of patients responds to front line VEGF directed therapy?
VEGF directed therapy still represents the mainstay of therapy for most patients with newly diagnosed metastatic RCC.
FDA-approved agents with category 1 recommendations include sunitinib, pazopanib, and bevacizumab/IFN-α.
What is the typical delay in cancer growth with these treatments?
Response rates range from 30% to 40% in the pivotal phase III studies assessing these agents in the front-line setting, with a delay in cancer growth (or progression-free survival, PFS) ranging from 9 to 12 months.
Importantly, these therapies are not curative—however, with the advent of new treatments for metastatic RCC, median survival has improved to roughly 3 years.